Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EMMANUEL JEAN-MARIE MIGNOT

Allopathic & Osteopathic Physicians Psychiatry & Neurology Sleep Medicine

NPI
1023151800
CMS profile
961917
Location
STANFORD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,844.54

7 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $2,400.00 1
Food and Beverage $444.54 6

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $2,671.72 5
JAZZ PHARMACEUTICALS INC. $150.00 1
Harmony Biosciences LLC $22.82 1

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EMMANUEL JEAN-MARIE MIGNOT

NPI 1023151800 · CMS profile ID 961917

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Sleep Medicine

STANFORD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023151800?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EMMANUEL JEAN-MARIE MIGNOT, NPI 1023151800, CMS profile ID 961917. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023151800?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). EMMANUEL JEAN-MARIE MIGNOT, NPI 1023151800, CMS profile ID 961917. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023151800?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
EMMANUEL JEAN-MARIE MIGNOT, NPI 1023151800, CMS profile ID 961917, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1023151800?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

7 matching records · $2,844.54 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 7 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–7 of 7.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $2,400.0011/21/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955734443 CMS
Takeda Pharmaceuticals U.S.A., Inc. $80.3409/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955734437 CMS
Takeda Pharmaceuticals U.S.A., Inc. $63.2206/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955734431 CMS
JAZZ PHARMACEUTICALS INC. $150.0006/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951392447 CMS
Harmony Biosciences LLC $22.8206/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955176309 CMS
Takeda Pharmaceuticals U.S.A., Inc. $119.9806/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955734425 CMS
Takeda Pharmaceuticals U.S.A., Inc. $8.1803/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955734419 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,292.12 9
PY2020 $14,160.00 5
PY2021 $23,131.44 17
PY2022 $2,844.54 7
PY2023 $4,565.65 9
PY2024 $40,598.94 22
PY2025 $47,971.34 26

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $992.00 1
PY2025 Principal investigator $2,401,878.07 533
PY2024 Principal investigator $1,022,037.24 254
PY2023 Principal investigator $275,388.22 59
PY2022 Principal investigator $175,960.37 12
PY2021 Principal investigator $361,355.25 19
PY2020 Recipient $3,276.62 36
PY2020 Principal investigator $214,065.50 29
PY2019 Recipient $921.37 2
PY2019 Principal investigator $67,788.78 53

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

254 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alkermes, Inc. $1,770.00 12/31/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1084814780
Principal investigator 1 Alkermes, Inc. $1,770.00 12/31/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1084814782
Principal investigator 1 Alkermes, Inc. $1,770.00 12/31/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1084814784
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 12/31/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081903
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 12/31/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081905
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 12/31/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081907
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 12/31/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081909
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8.72 12/18/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1125501170
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $87.04 12/18/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1125501172
Principal investigator 1 Vanda Pharmaceuticals Inc. $720.00 12/18/2024 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN DELAYED SLEEP-WAKE PHASE DISORDER (DSWPD) No dispute reported 06/30/2026 1133925952
Principal investigator 1 Eisai Inc. $128.00 12/16/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1106532002
Principal investigator 1 Eisai Inc. $27,817.60 12/16/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1106532004
Principal investigator 1 Eisai Inc. $819.00 12/16/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1106532006
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,451.33 12/04/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071646
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6,897.92 12/04/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071648
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,904.64 12/04/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071650
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7,299.84 12/04/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071652
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7,299.84 12/04/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071654
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,403.20 12/04/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071656
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7,299.84 12/04/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071658
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7,299.84 12/04/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071660
Principal investigator 1 Alkermes, Inc. $1,770.00 11/29/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1084814774
Principal investigator 1 Alkermes, Inc. $1,770.00 11/29/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1084814776
Principal investigator 1 Alkermes, Inc. $1,770.00 11/29/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1084814778
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 11/29/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081899
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 11/29/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081901
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 11/29/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081913
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 11/29/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081915
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $26.30 11/04/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081895
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $52.60 11/04/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081897
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 10/31/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081889
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 10/31/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081891
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 10/31/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081893
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 10/31/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081911
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,904.64 10/25/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071638
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4,993.28 10/25/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071640
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,403.20 10/25/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071642
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6,231.95 10/25/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071644
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,484.00 10/16/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1125498481
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,584.00 10/16/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1125498483
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,200.00 10/16/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1125498485
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,000.00 10/16/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1125498487
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,960.96 10/16/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1125498489
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,200.00 10/16/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1125498491
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $851.20 10/16/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1125498493
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,404.80 10/16/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1125498495
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $19,471.97 10/16/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1125498581
Principal investigator 1 Alkermes, Inc. $1,770.00 09/30/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814766
Principal investigator 1 Alkermes, Inc. $1,770.00 09/30/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814768
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 09/30/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081877
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 09/30/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081879
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 09/30/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081881
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 09/30/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081885
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $46,992.04 09/18/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1125478234
Principal investigator 1 Alkermes, Inc. $70.00 09/05/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814764
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,563.84 09/04/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071614
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7,966.72 09/04/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071616
Principal investigator 1 Alkermes, Inc. $619.70 09/03/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1084814770
Principal investigator 1 Alkermes, Inc. $259.70 09/03/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1084814772
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $66.00 08/30/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071632
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 08/30/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081871
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 08/30/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081873
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 08/30/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081875
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 08/30/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081883
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,137.24 08/21/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478206
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,118.68 08/16/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478200
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $925.44 08/16/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478202
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $113.40 08/14/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478188
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,130.30 08/14/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478190
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,616.26 08/14/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478192
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $704.00 08/14/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478194
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $814.39 08/07/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071618
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4,993.28 08/07/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071620
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7,299.84 08/07/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071636
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $22,562.92 08/07/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478176
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,732.80 08/07/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478178
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,536.00 08/02/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478158
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,702.40 08/02/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478160
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,321.92 08/02/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478162
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,100.80 08/02/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478164
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,174.72 08/02/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478166
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $850.00 08/02/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478168
Principal investigator 1 Eisai Inc. $128.00 08/01/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1106531980
Principal investigator 1 Eisai Inc. $3,276.00 08/01/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1106531990
Principal investigator 1 Eisai Inc. $11,127.04 08/01/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1106532000
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $768.00 08/01/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478142
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 07/31/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081863
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 07/31/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081865
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 07/31/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081867
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 07/31/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081869
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,142.80 07/26/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478130
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $144.00 07/26/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478132
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $384.00 07/26/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478134
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,370.69 07/26/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478136
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,702.40 07/24/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478118
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 07/24/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478120
Principal investigator 1 Eisai Inc. $44,508.16 07/22/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1106531974
Principal investigator 1 Eisai Inc. $1,024.00 07/22/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1106531986
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,704.64 07/19/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478110
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $384.00 07/19/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478112
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7,299.84 07/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071612
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7,299.84 07/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071634
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3.30 07/02/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071622
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $33.00 07/02/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071624
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9.60 07/02/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071626
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.99 07/02/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071628
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2.88 07/02/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071630
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $456.10 07/02/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081861
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $45.42 07/02/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081887
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 06/28/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081849
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 06/28/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081851
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 06/28/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081853
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 06/28/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081857
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,651.20 06/26/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478078
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,536.00 06/26/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478080
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,082.88 06/26/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478082
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,024.72 06/26/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478084
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,000.00 06/21/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478076
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 06/20/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478072
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,400.00 06/20/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478074
Principal investigator 1 Alkermes, Inc. $156.32 06/03/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084816274
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,904.64 06/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071594
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,403.20 06/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071596
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6,897.92 06/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071608
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 05/31/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081829
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 05/31/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081831
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 05/31/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081833
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 05/31/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081835
Principal investigator 1 Alkermes, Inc. $45.90 05/24/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814760
Principal investigator 1 Alkermes, Inc. $20.59 05/24/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814762
Principal investigator 1 Alkermes, Inc. $190.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814698
Principal investigator 1 Alkermes, Inc. $259.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814700
Principal investigator 1 Alkermes, Inc. $259.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814702
Principal investigator 1 Alkermes, Inc. $259.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814704
Principal investigator 1 Alkermes, Inc. $259.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814706
Principal investigator 1 Alkermes, Inc. $125.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814708
Principal investigator 1 Alkermes, Inc. $50.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814710
Principal investigator 1 Alkermes, Inc. $20.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814712
Principal investigator 1 Alkermes, Inc. $50.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814714
Principal investigator 1 Alkermes, Inc. $20.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814716
Principal investigator 1 Alkermes, Inc. $190.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814718
Principal investigator 1 Alkermes, Inc. $259.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814720
Principal investigator 1 Alkermes, Inc. $125.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814722
Principal investigator 1 Alkermes, Inc. $50.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814724
Principal investigator 1 Alkermes, Inc. $20.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814726
Principal investigator 1 Alkermes, Inc. $50.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814728
Principal investigator 1 Alkermes, Inc. $20.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814730
Principal investigator 1 Alkermes, Inc. $190.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814732
Principal investigator 1 Alkermes, Inc. $259.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814734
Principal investigator 1 Alkermes, Inc. $125.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814736
Principal investigator 1 Alkermes, Inc. $50.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814738
Principal investigator 1 Alkermes, Inc. $20.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814740
Principal investigator 1 Alkermes, Inc. $50.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814742
Principal investigator 1 Alkermes, Inc. $20.00 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814744
Principal investigator 1 Alkermes, Inc. $34.45 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814746
Principal investigator 1 Alkermes, Inc. $21.27 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814748
Principal investigator 1 Alkermes, Inc. $29.48 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814750
Principal investigator 1 Alkermes, Inc. $3.68 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814752
Principal investigator 1 Alkermes, Inc. $18.58 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814754
Principal investigator 1 Alkermes, Inc. $29.47 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814756
Principal investigator 1 Alkermes, Inc. $41.17 05/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814758
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,485.36 05/22/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478060
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $62,939.00 05/21/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
Protein biomarkers of T1, T2 narcolepsy and idiopathic hypersomnia (Preclinical) No dispute reported 06/30/2026 1150085353
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,200.00 05/17/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071588
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,584.00 05/17/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071590
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $594.51 05/17/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071592
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,840.00 05/17/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071604
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $12,608.00 05/17/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071606
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,560.00 05/17/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478044
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,432.00 05/17/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478046
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $845.00 05/17/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478048
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,084.80 05/17/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478050
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,840.00 05/17/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478052
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,584.00 05/17/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478054
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,200.00 05/17/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478056
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,200.00 05/17/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478058
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,610.00 05/15/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081837
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $11,290.00 05/15/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081839
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,584.00 05/15/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081841
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,200.00 05/15/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081843
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,840.00 05/15/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081859
Principal investigator 1 Alkermes, Inc. $733.93 05/02/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814696
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $56.10 05/02/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071602
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $45.61 05/02/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071610
Principal investigator 1 Alkermes, Inc. $741.63 05/01/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814694
Principal investigator 1 Eisai Inc. $819.00 05/01/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1106531972
Principal investigator 1 Eisai Inc. $22,254.08 05/01/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1106531976
Principal investigator 1 Eisai Inc. $6,552.00 05/01/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1106531984
Principal investigator 1 Eisai Inc. $256.00 05/01/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1106531996
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 04/30/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081827
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 04/30/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081845
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 04/30/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081847
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 04/30/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081855
Principal investigator 1 Alkermes, Inc. $733.93 04/23/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1084814692
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,537.06 04/19/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478026
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $50.84 04/02/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071598
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $110.00 04/02/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071600
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 03/29/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081813
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/29/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081815
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 03/29/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081817
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 03/29/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081823
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,600.00 03/27/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478020
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,404.80 03/27/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478022
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 03/27/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125478024
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,663.97 03/13/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1125477994
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/29/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081809
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/29/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081811
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/29/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081819
Principal investigator 1 Eisai Inc. $10,438.00 02/27/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1106532008
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,753.02 02/23/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1125477990
Principal investigator 1 HARMONY BIOSCIENCES LLC $13,670.40 02/08/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia No dispute reported 06/30/2026 1127772235
Principal investigator 1 Eisai Inc. $1,838.00 02/05/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1106531982
Principal investigator 1 Eisai Inc. $7,000.00 02/05/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1106531988
Principal investigator 1 Eisai Inc. $55,635.20 02/05/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1106531992
Principal investigator 1 Eisai Inc. $16,380.00 02/05/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1106531994
Principal investigator 1 Eisai Inc. $348.00 02/05/2024 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1106531998
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $22.69 02/01/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081777
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $14.88 02/01/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081779
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $31.21 02/01/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081781
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.78 02/01/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081783
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.32 02/01/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081785
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $39.45 02/01/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081787
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $65.75 02/01/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081789
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $13.15 02/01/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081791
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $13.15 02/01/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081793
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.32 02/01/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081795
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.57 02/01/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081797
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $132,485.23 02/01/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125477976
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $36,924.07 02/01/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1125477978
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081799
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $492.00 01/31/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081801
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081821
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $714.00 01/31/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081825
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $24,040.90 01/26/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125477974
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $66.00 01/21/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081803
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $88.00 01/21/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081805
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $95.01 01/21/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1150081807
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,003.90 01/12/2024 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1125477972
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $33.00 01/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071556
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $178.05 01/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071558
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4.80 01/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071560
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.98 01/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071562
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $46.87 01/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071564
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $45.61 01/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071566
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5.76 01/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071568
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9.57 01/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071570
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $140.58 01/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071572
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $28.05 01/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071574
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $221.38 01/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071576
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.71 01/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071578
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.41 01/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071580
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $90.84 01/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071582
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $50.84 01/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071584
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.90 01/03/2024 Non-covered Recipient Entity
Board of Trustees of the Leland Stanford Junior University
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150071586